Clinical trials: Respiratory Inflammation
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with…
- Trial name
- SOLANA (NCT02869438)
- Testing
- Benralizumab
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic inflammation. The study will investigate the paradigm of multiple receptor antagonism in allergic disease by combining QAV680 with a…
- Trial name
- NCT01103050
- Testing
- QAV680 + Cetirizine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
Pneumonia
A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia
The purpose of this study is evaluation of the safety and effectiveness of levofloxacin, an antibiotic, compared with ceftriaxone sodium or cefuroxime axetil in the treatment of adults with pneumonia.
- Trial name
- NCT00257049
- Testing
- levofloxacin
- Volunteers
- 604 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
- Trial name
- NCT00584584
- Testing
- QAX576
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04299152
- Testing
- Stem Cell Educator-Treated Mononuclear Cells Apheresis
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Interstitial Lung Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD.
- Trial name
- NCT05892614
- Testing
- efzofitimod 450 mg, efzofitimod 270 mg
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- aTyr Pharma, Inc.
Sepsis, COVID-19
SQuISH-COVID: A Pilot Study
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious…
- Trial name
- NCT04372472
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cytovale, Inc.
Acute Respiratory Distress Syndrome
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07479043
- Testing
- Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Controls will receive two infusions of vehicle solution.
- Volunteers
- 128 people
- Sponsor
- Breathe Biologics, Inc.
Bronchiolitis
Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis
The investigators reasoned that a hypertonic saline concentration higher than 3% could be safe and more efficacious in the treatment of bronchiolitis, alleviating severe symptoms and preventing the need for hospitalization in…
- Trial name
- NCT01016249
- Testing
- Treatment 1. (5% Hypertonic saline + Epinephrine), Treatment 3. (3% Hypertonic saline + Epinephrine), Treatment 2. (Normal saline + Epinephrine)
- Where
- Qatar
- Volunteers
- 187 people
- Sponsor
- Hamad Medical Corporation
Infection
Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
This study is a post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Ciproxan intravenously as a first-line treatment for sepsis, secondary skin infections…
- Trial name
- NCT01670435
- Testing
- Ciprofloxacin (BAYQ3939)
- Where
- Japan
- Volunteers
- 3,274 people
- Sponsor
- Bayer
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups.
- Trial name
- AEOLUS (NCT07053423)
- Testing
- Dupilumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- Sanofi